Indication
Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients not adequately controlled on their maximally tolerated dose of metformin alone in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Segluromet 2,5 MG/1.000 MG Comprimidos Recubiertos con PeliculaSpain · 3,238 mg + 1000 mgMarketed
- Segluromet 7,5 MG/1.000 MG Comprimidos Recubiertos con PeliculaSpain · 9,713 mg + 1000 mgAuthorised
- Segluromet 2,5 mg/1000 mg filmomhulde tablettenNetherlandsAuthorised
- Segluromet 2,5 mg/850 mg filmomhulde tablettenNetherlands